BioNTech has announced the acquisition of fellow German biotech CureVac in an all-stock transaction valued at approximately $1.25 billion. Under the agreement, CureVac shareholders will receive about ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

Fintel reports that on June 26, 2025, UBS downgraded their outlook for CureVac N.V. (NasdaqGM:CVAC) from Buy to Neutral.

The growing incidence of infectious diseases, cancer, and chronic illnesses has substantially increased the demand for ...

Emittent / Herausgeber: CureVac / Schlagwort (e): Hauptversammlung CureVac Announces Voting Results of General Meeting 24.06.2025 / 22:09 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / ...

TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational ...

CureVac Announces Voting Results of General Meeting TÜBINGEN, Germany / BOSTON, USA - June 24, 2025 - CureVac N.V. (Nasdaq: ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.

Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week.

Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are ...